Product Description
Izokibep is a unique antibody mimetic and potent interleukin-17A (IL-17A) inhibitor designed to overcome the limitations of existing monoclonal antibodies.
Mechanisms of Action: IL17A Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: ACELYRIN
Company Location:
Company CEO:
Additonal Commercial Interests: Affibody
Clinical Description
Countries in Clinic: Austria, Bulgaria, Canada, China, Czech Republic, France, Germany, Hungary, Italy, Japan, Poland, Spain, United States, Unknown Location
Active Clinical Trial Count: 12
Highest Development Phases
Phase 3: Arthritis, Psoriatic|Hidradenitis Suppurativa
Phase 2: Panuveitis|Spondylitis, Ankylosing|Uveitis|Uveitis, Intermediate|Uveitis, Posterior
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
jRCT2031230501 | P3 |
Not yet recruiting |
Hidradenitis Suppurativa |
2025-12-31 |
|
22107 | P3 |
Unknown Status |
Hidradenitis Suppurativa |
2025-12-17 |
|
NCT05384249 | P2 |
Active, not recruiting |
Panuveitis |
2025-08-07 |
|
21103 | P2 |
Unknown Status |
Uveitis, Posterior|Uveitis, Intermediate |
2025-06-19 |